Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2151 - 2175 of 15273 in total
Approved
Vet approved
An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and...
Approved
Withdrawn
Matched Description: … prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy. ... [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the …
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of...
Approved
Matched Iupac: … }.0^{34,39}]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
Matched Description: … kidneys and the inner ear. ... It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to ... liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.
Approved
Investigational
Matched Description: … in combination with estrogen, for the therapy of severe acne and hirsutism in females. ... It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, …
Matched Categories: … Antiandrogens and Estrogens ... cyproterone and estrogen ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Combination Contraceptives (with Estrogen and derivatives) …
Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by...
Approved
Investigational
Matched Iupac: … 1S,2S,3R,4R)-4-carbamimidamido-3-[(1S)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic acid
Matched Description: … The development of peramivir has been supported by the US Department of Health and Human Services as ... the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and ... in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and
Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut...
Approved
Investigational
Matched Description: … Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated ... Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and ... By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system …
Matched Categories: … Antiemetics and Antinauseants ... Alimentary Tract and Metabolism …
Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3).[A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint...
Approved
Investigational
Matched Description: … Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte ... was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,[A246155] and ... has garnered interest in the treatment of a variety of cancers, including leukemia[A246160] and melanoma …
Matched Categories: … nivolumab and relatlimab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Multiple myeloma is a cancer where plasma cells rapidly divide out of control. These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells. Multiple myeloma is typically treated with an immunomodulatory agent like lenalidomide, a proteasome inhibitor like bortezomib, or an anti-CD38 monoclonal...
Approved
Matched Description: … [A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from ... known as bb2121, is a chimeric antigen receptor (CAR) T-cell therapy like [axicabtagene ciloleucel] and ... vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic cell and gene therapy ... Receptors, Cytoplasmic and Nuclear ... Antineoplastic and Immunomodulating Agents …
Oxyphenisatin acetate is the pro-drug of oxyphenisatin (3,3-bis(4-hydroxyphenyl)-1H-indol-2-one). The FDA withdrew its approval for the use of oxyphenisatin acetate due to safety reasons.
Approved
Investigational
Withdrawn
Pentetreotide has been used in trials studying the diagnosis of Cushing's syndrome.
Approved
Investigational
Matched Iupac: … ]carbamoyl}methyl)(carboxymethyl)amino]ethyl}(carboxymethyl)amino)ethyl](carboxymethyl)amino}acetic acid
Matched Categories: … Indicators and Reagents ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Sacrosidase is a liquid enzyme preparation from S.cerevisiae used for the treatment of congenital sucrose-isomaltase deficiency (CSID). People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and children. Treatment options for these patients...
Approved
Matched Description: … People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues ... Treatment options for these patients are limited and usually consists of a lifelong sucrose-free diet ... metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants With Advanced Parkinson's Disease).
Approved
Investigational
Matched Iupac: … (2S)-2-amino-3-[3-hydroxy-4-(phosphonooxy)phenyl]propanoic acid
Matched Description: … Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and
Matched Categories: … Dopa and Dopa Derivatives ... foslevodopa and decarboxylase inhibitor …
Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizimâ„¢. The recommended dose is 2 mg per kg given intravenously over...
Approved
Investigational
Matched Description: … Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Chondroitinases and Chondroitin Lyases …
Phenolphthalein was withdrawn in Canada due to concerns with carcinogenicity in 1997.
Approved
Withdrawn
Matched Categories: … Indicators and Reagents ... Alimentary Tract and Metabolism …
Propiverine is a widely used antimuscarinic drug with a mixed mode of action in the treatment of symptoms associated with overactive bladder (OAB) . Overactive bladder (OAB) is a chronic condition of the lower urinary tract characterized by urinary urgency, increased frequency of urination, and nocturia (frequent waking during the...
Approved
Investigational
Matched Description: … prevalence in men and women. ... OAB has a negative impact on quality of life and may lead to leakage and inconvenient urinary accidents ... Overactive bladder syndrome affects millions of elderly individuals in the United States and shows equal …
Matched Categories: … Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …
Spinosad is a pediculicide mixture of spinosyn A and spinosyn D (in an approximately 5:1 ratio, respectively) used in the topical treatment of head lice in children (four years old and older) and in adults. Spinosad is an insecticide based on a compound found in S. spinosa, a bacterial species....
Approved
Investigational
Vet approved
Matched Description: … ) used in the topical treatment of head lice in children (four years old and older) and in adults. ... Spinosad is a pediculicide mixture of spinosyn A and spinosyn D (in an approximately 5:1 ratio, respectively ... Spinosad has also been experimented for use in cats for treatment of flea infestations, and has also …
Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
Approved
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Anterior Pituitary Lobe Hormones and Analogues ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Insulin icodec is an ultra long-acting basal insulin analogue.
Approved
Investigational
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Tibolone is a synthetic steroid hormone drug, which is mainly non-selective in its binding profile, acting as an agonist primarily at estrogen receptors (ER), with a preference for ER alpha . Tibolone (Livial, Org OD 14), produced by Organon (West Orange, NJ), is a synthetic steroid that possesses estrogenic, androgenic...
Approved
Investigational
Matched Description: … produced by Organon (West Orange, NJ), is a synthetic steroid that possesses estrogenic, androgenic and ... Tibolone is approved in 90 countries to manage menopausal symptoms and in 45 countries to prevent the ... been used in Europe for almost 2 decades, primarily for the prevention of postmenopausal osteoporosis and
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists ... Estrogens, Antiestrogens, and Estrogen Agonist-Antagonists …
Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is...
Approved
Investigational
Matched Description: … [A183206] Lefamulin is available in intravenous and oral preparations and was granted FDA approval in …
Matched Categories: … Sulfur Compounds …
Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release....
Approved
Matched Description: … and electrolyte disturbances. ... [A255647] Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular ... A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and
Matched Categories: … Sulfur Compounds …
Nepafenac is a non-steroidal anti-inflammatory prodrug (NSAID) usually sold as a prescription eye drop. It is used to treat pain and inflammation associated with cataract surgery.
Approved
Investigational
Matched Description: … It is used to treat pain and inflammation associated with cataract surgery. …
Amivantamab, also known as JNJ-61186372, is an anti-EGFR-MET bispecific antibody, derived from Chinese hamster ovary cells, approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose...
Approved
Investigational
Matched Description: … FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and ... [A235103,L34193] Patients with NSCLC often develop resistance to drugs that target EGFR and MET individually ... Patients with NSCLC with exon 20 insertion mutations in EGFR do not respond to tyrosine kinase inhibitors, and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Lupus nephritis (LN) is a type of glomerulonephritis occurring in patients with systemic lupus erythematosus (SLE). LN is a significant cause of renal failure, morbidity, and death in patients with SLE. Within 10 years of being diagnosed with SLE, 5-20% of those suffering from LN develop end-stage kidney disease, a...
Approved
Investigational
Matched Description: … Early and accurate intervention for LN is important in improving clinical outcomes. ... LN is a significant cause of renal failure, morbidity, and death in patients with SLE. ... [L31208] Voclosporin has demonstrated a more stable pharmacokinetic and pharmacodynamic relationship …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to cidoxepin. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but...
Approved
Investigational
Matched Description: … Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. ... [L5977] Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. ... [T559] It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer …
Matched Categories: … Acid Reducers ... Hypnotics and Sedatives ... Antipruritics and Local Anesthetics ... Tricyclics and Other Norepinephrine-reuptake Inhibitors …
Displaying drugs 2151 - 2175 of 15273 in total